HC Advisors LLC Invests $229,000 in Becton, Dickinson and Company $BDX

HC Advisors LLC bought a new position in Becton, Dickinson and Company (NYSE:BDX) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,000 shares of the medical instruments supplier’s stock, valued at approximately $229,000.

Several other institutional investors have also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $27,000. Alpine Bank Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $29,000. REAP Financial Group LLC boosted its stake in shares of Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 55 shares during the period. Cornerstone Planning Group LLC boosted its stake in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 99 shares during the period. Finally, Nexus Investment Management ULC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $34,000. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

BDX has been the subject of a number of recent analyst reports. Barclays lowered their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research note on Tuesday, June 3rd. William Blair lowered shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 1st. Morgan Stanley lifted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Piper Sandler restated a “neutral” rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $211.44.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $195.22 on Tuesday. The company has a market capitalization of $55.96 billion, a PE ratio of 35.11, a P/E/G ratio of 1.47 and a beta of 0.20. The company has a 50-day simple moving average of $178.66 and a two-hundred day simple moving average of $196.21. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter in the previous year, the firm earned $3.50 EPS. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Claire Fraser sold 863 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $192.30, for a total value of $165,954.90. Following the transaction, the director directly owned 23,143 shares in the company, valued at $4,450,398.90. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,214 shares of company stock valued at $579,206 in the last quarter. 0.36% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.